Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.67 (
thiopurine methyltransferase
)
551
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In light of the increasing need by decision makers for a method of evaluating genomic applications based on the weight of evidence for their efficacy, several agencies have developed systems of classification. Here I review the horizon-scanning method for prioritizing genomics applications as described by Dotson et al. in this issue of
CPT
. Using the examples of the authors' Tier 1/Green classification for KRAS and Tier 2/Yellow for
TPMT
, I discuss differences between the guidelines issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and those by the National Comprehensive Cancer Network (NCCN). Additionally, I offer suggestions regarding classification of the Tier 3/Red genomics applications and the reproducibility of the data-curating algorithm of the horizon-scanning method.
...
PMID:A horizon-prioritizing method can identify gaps among genomic application guidelines. 2439 97